Geron Plans to Present at Upcoming Investor Conferences

Core Viewpoint - Geron Corporation is focused on transforming the treatment landscape for blood cancer through its innovative therapies, particularly its first-in-class telomerase inhibitor, RYTELO (imetelstat) [2]. Company Overview - Geron is a commercial-stage biopharmaceutical company dedicated to changing lives by altering the course of blood cancer [2]. - RYTELO (imetelstat) has received approval in the United States and the European Union for treating certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) who have transfusion-dependent anemia [2]. - The company is conducting a pivotal Phase 3 clinical trial of imetelstat in patients with JAK-inhibitor resistant/refractory myelofibrosis (R/R MF) and is also exploring its use in other hematologic malignancies [2]. - The mechanism of action involves inhibiting telomerase activity, which is elevated in malignant stem and progenitor cells in the bone marrow, potentially reducing proliferation and inducing death of malignant cells [2]. Investor Engagement - Geron management is scheduled to present at several upcoming investor conferences, including: - TD Cowen 46th Annual Healthcare Conference on March 2 at 1:10 p.m. ET in Boston, MA [3]. - Barclays 28th Annual Global Healthcare Conference on March 10 at 10:30 a.m. ET in Miami, FL [3]. - Leerink Partners Global Healthcare Conference with in-person meetings on March 11 in Miami, FL [3]. - Live and archived audio webcasts of these presentations will be available on Geron's website [1].